Print page |
Email page
| 
Download PDF
« Previous Release | Next Release »
New York, NY, August 16, 2005 - Intrac, Inc. (OTC BB: ITRD) and its wholly-owned
subsidiary Innovative Drug Delivery Systems (IDDS) is presenting data today on the use
of intranasal Ketamine for acute pain at the Department of Defense's premier scientific
event, the Advanced Technology Applications for Combat Casualty Care (ATACCC) 2005
Conference.
This year's meeting focuses on battlefield medical care issues during combat operations in
support of Operation Iraqi Freedom and on the technologies available today and in the
future that can be used to meet the increasingly complex medical needs of combat
casualties.
"IDDS is focused on enhancing the available options for sufferers of moderate-to-severe
acute pain," stated Daniel B. Carr, M.D., chief executive and chief medical officer of
IDDS. "Intranasal Ketamine, a self-administered, needle-free, fast-acting pain reliever, is an ideal alternative to the traditional medic-administered morphine currently used on the modern battlefield."
About PMI-150
Intranasal Ketamine or PMI-150 is a patient-controlled nasal spray that delivers a metered dose of ketamine, a non-opioid analgesic used for treatment of moderate-to-severe pain.
Ketamine's 30-year record as safe, effective and non-addictive with virtually no side
effects makes it an ideal pain management solution.
About IDDS
IDDS is a specialty pharmaceutical company, applying innovative proprietary technologies
to develop new drugs and improved formulations of existing drugs to target unmet and underserved medical needs in the pain management market.
This news release contains forward-looking statements. Such statements are valid only as
of today, and we disclaim any obligation to update this information. These statements are
subject to known and unknown risks and uncertainties that may cause actual future
experience and results to differ materially from the statements made. These statements
are based on our current beliefs and expectations as to such future outcomes. Drug
discovery and development involve a high degree of risk. Factors that might cause such a
material difference include, among others, uncertainties related to the ability to attract and
retain partners for our technologies, the identification of lead compounds, the successful
preclinical development thereof, the completion of clinical trials, the FDA review process
and other governmental regulation, our ability to obtain working capital, our ability to
successfully develop and commercialize drug candidates, and competition from other
pharmaceutical companies.
| Investor Contact: | Media Contact: |
| The Investor Relations Group | The Investor Relations Group |
| Christie Mazurek / Ross D'Eredita | Janet Vasquez |
| (212) 825-3210 | (212) 825-3210 |